Photo of Kathryn A. Chung, M.D.

Kathryn A. Chung M.D.

Dr. Chung earned her medical degree from the University of Alberta. She is board certified in internal medicine (1998) and neurology (2003). She received her training in movement disorders from OHSU.

She joined the OHSU movement disorders faculty in 2004. She is currently an associate professor of neurology with the OHSU Parkinson Center and the Parkinson's Disease Research, Education, and Clinical Center (PADRECC) at the Portland VAMC.

Her research interests are focused primarily on Parkinson's disease. Her special interests are the understanding and treatment of dyskinesia, gait and balance abnormailities, neuroprotective strategies, and the study of biomarkers in Parkinson's disease.

Dr. Chung is an expert clinician for all movement disorders and Tourettes syndrome.

Read more
  • Residency:

    • Internal medicine, University of Toronto, Canada
  • Fellowship:

    • Movement disorders, Portland Veterans Affairs Medical Center, 2004
  • Certifications:

    • Internal medicine, 1998

Publications

  • "Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in parkinson disease." JAMA Neurology In: , Vol. 73, No. 10, 01.10.2016, p. 1217-1224.
  • "GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease." Movement Disorders In: , Vol. 31, No. 1, 01.01.2016, p. 95-102.
  • "Cognition in individuals at risk for Parkinson's : Parkinson associated risk syndrome (PARS) study findings." Movement Disorders  In: , Vol. 31, No. 1, 01.01.2016, p. 86-94.
  • "Effect of augmenting cholinergic function on gait and balance." BMC Neurology In: , Vol. 15, No. 1, 264, 23.12.2015.
  • "The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease." Molecular Neurodegeneration In: , Vol. 10, No. 1, 50, 24.09.2015.
  • "Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease." Parkinsonism and Related Disorders In: , Vol. 21, No. 7, 01.07.2015, p. 692-697.
  • "Recognizing and treating neuropsychiatric symptoms in parkinson's disease." Journal of Clinical Outcomes Management In: , Vol. 22, No. 7, 01.07.2015, p. 323-334.
  • "Cognitive profile of LRRK2-related Parkinson's disease." Movement Disorders In: , Vol. 30, No. 5, 15.04.2015, p. 728-733.
  • "APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease." JAMA Neurology In: , Vol. 71, No. 11, 01.11.2014, p. 1405-1412.
  • "Evaluation of mild cognitive impairment subtypes in Parkinson's disease." Movement Disorders In: , Vol. 29, No. 6, 2014, p. 756-764.
  • "People with parkinson's disease and normal MMSE score have a broad range of cognitive performance." Movement Disorders In: , Vol. 29, No. 10, 2014, p. 1258-1264.
  • "Bilateral deep brain stimulation targeting ventralis intermedius nucleus to treat a professional musician's task-specific tremor." Movement Disorders  In: , Vol. 28, No. 13, 11.2013, p. 1896-1897.
  • "Which dyskinesia scale best detects treatment response?" Movement Disorders  In: , Vol. 28, No. 3, 03.2013, p. 341-346.
  • "APOE ε4 increases risk for dementia in pure synucleinopathies." JAMA Neurology In: , Vol. 70, No. 2, 2013, p. 223-228.
  • "Pacific northwest udall center of excellence clinical consortium : Study design and baseline cohort characteristics." Journal of Parkinson's Disease In: , Vol. 3, No. 2, 2013, p. 205-214.
  • "Common variation in the LRRK2 gene is a risk factor for Parkinson's disease." Movement disorders : official journal of the Movement Disorder Society In: , Vol. 27, No. 14, 12.2012, p. 1822-1825.
  • "Common variation in the LRRK2 gene is a risk factor for Parkinson's disease." Movement Disorders In: , Vol. 27, No. 14, 12.2012, p. 1823-1826.
  • "Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome study." Movement Disorders  In: , Vol. 27, No. 3, 03.2012, p. 406-412.
  • "Phosphorylated α-synuclein in Parkinson's disease." Science Translational Medicine  In: , Vol. 4, No. 121, 15.02.2012.
  • "Alternative processing of γ-secretase substrates in common forms of mild cognitive impairment and alzheimer's disease : Evidence for γ-secretase dysfunction." Annals of Neurology  In: , Vol. 69, No. 6, 06.2011, p. 1026-1031.
  • "Complement 3 and factor H in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy." American Journal of Pathology  In: , Vol. 178, No. 4, 04.2011, p. 1509-1516.
  • "Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression." Annals of Neurology  In: , Vol. 69, No. 3, 03.2011, p. 570-580.
  • "CSF Aβ42 and tau in Parkinson's disease with cognitive impairment." Movement Disorders  In: , Vol. 25, No. 15, 11.2010, p. 2682-2685.
  • "SNCA variant associated with Parkinson disease and plasma α-synuclein level." Archives of Neurology In: , Vol. 67, No. 11, 11.2010, p. 1350-1356.
  • "Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease." Neurology In: , Vol. 75, No. 14, 05.10.2010, p. 1263-1269.
  • "Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease." Neuroscience Letters  In: , Vol. 480, No. 1, 08.2010, p. 78-82.
  • "Objective measurement of dyskinesia in Parkinson's disease using a force plate." Movement Disorders  In: , Vol. 25, No. 5, 15.04.2010, p. 602-608.
  • "Dyskinesia and the antiparkinsonian response always temporally coincide : A retrospective study." Neurology  In: , Vol. 74, No. 15, 04.2010, p. 1191-1197.
  • "DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease." Brain  In: , Vol. 133, No. 3, 03.2010, p. 713-726.
  • "Glycoproteomics in neurodegenerative diseases." Mass Spectrometry Reviews  In: , Vol. 29, No. 1, 01.2010, p. 79-125.

Additional information

Edit profile